Ionis: 3 Key Takeaways for Long-Term Investors

Ionis lowered its 2026 TRYNGOLZA revenue guidance to ~$50 million due to a slower-than-anticipated launch ramp, while DAWNZERA showed strong momentum with 40% quarterly sales growth to $37 million. However, Phase III clinical trial setbacks in partnered programs forced management to delay its positive cash flow target from 2028 to 2029, though the company maintains a $1.9 billion cash position.